Category: Latest News

Multiple sclerosis (MS) clinicians and research were well represented when neurologists from across the country and around the world gathered in Boston in April for the 75th Annual Meeting of the American Academy of Neurology (AAN). Indeed, findings from more than 270 studies on various aspects of MS were presented at the meeting.

The Multiple Sclerosis Association of America (MSAA), the Chronic Health Improvement Research Program (CHIRP) at Dartmouth Health, and Novartis Pharmaceuticals Corporation (“Novartis”) are collaborating to launch the Multiple Sclerosis Implementation Network™ (MSIN™). This is a first-of-its-kind initiative to develop a multi-center learning health network for providers to support people living with multiple sclerosis (MS).

MSAA has partnered with Talkspace, an online mental health service, to create an innovative pilot program for individuals with MS to receive three months of online therapy at no cost. Talkspace connects people to thousands of dedicated providers via a secure and confidential, HIPAA-compliant platform.

The Multiple Sclerosis Association of America (MSAA) is excited to gather together for our 9th Annual Improving Lives Benefit this May. We are delighted to announce two opportunities to attend, including an in-person reception and a virtual program highlighting key members of the MS community.

Reviewed by MSAA Chief Medical …

The Multiple Sclerosis Association of America (MSAA) proudly recognizes March as Multiple Sclerosis Awareness Month and is pleased to present four weeks full of valuable and inspiring resources, programs, and strategies for all ages. We are dedicated to spreading awareness, education, and support to individuals, families, and care partners in the MS community, and this month is no different.

The studies featured in this edition of “What’s New in MS Research” speak to progress made and progress awaited. We start out by announcing two new disease-modifying therapies that are or soon will be available through one’s healthcare provider.

TG Therapeutics has announced that the United States Food and Drug Administration (FDA) approved Briumvi™ (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis (MS) in adults – including clinically isolated syndrome, relapsing-remitting MS, and active secondary-progressive MS. This medication is a monoclonal antibody that targets CD20, a protein found on the surface of B cells, and induces B-cell depletion within 24 hours. B cells are white blood cells shown to play a role in MS.

Experts in every aspect of multiple sclerosis (MS) gathered in Amsterdam, The Netherlands, in late October 2022 to unveil research results and share ideas at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). With more than 1,200 bridges, the Dutch capital was an appropriate location for a meeting dedicated to connecting the findings from laboratory research and clinical trials to enhancements in patient care.

On Friday, November 18, 2022, …